NASDAQ:STML Stemline Therapeutics (STML) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free STML Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$11.83▼$11.8350-Day Range$11.83▼$11.8352-Week Range$3.21▼$18.22Volume1,084 shsAverage Volume1.52 million shsMarket Capitalization$621.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Stemline Therapeutics alerts: Email Address Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About Stemline Therapeutics Stock (NASDAQ:STML)Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.Read More Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. STML Stock News HeadlinesApril 10, 2022 | thestreet.comTrade These 7 Stocks Under $10 for Huge ProfitsOctober 26, 2021 | finance.yahoo.comBreakeven On The Horizon For Stemline Therapeutics Inc (NASDAQ:STML)See More Headlines Receive STML Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stemline Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2019Today5/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:STML CUSIPN/A CIK1264587 Webwww.stemline.com Phone646-502-2311FaxN/AEmployees92Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,820,000.00 Net Margins-150.30% Pretax MarginN/A Return on Equity-48.14% Return on Assets-41.35% Debt Debt-to-Equity RatioN/A Current Ratio7.43 Quick Ratio7.37 Sales & Book Value Annual Sales$43.22 million Price / Sales14.37 Cash FlowN/A Price / Cash FlowN/A Book Value$3.26 per share Price / Book3.63Miscellaneous Outstanding Shares52,511,000Free FloatN/AMarket Cap$621.21 million OptionableOptionable Beta1.78 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Ivan Bergstein (Age 53)Founder, Pres, CEO & Chairman Mr. David G. Gionco (Age 59)VP of Fin. & Chief Accounting Officer Mr. Kenneth Hoberman (Age 54)COO & Corp. Sec. Mr. Robert FrancomanoSr. VP & Global Head of CommercialMr. John A. SalvagnoSr. VP of Quality & OperationsKey CompetitorsCogent BiosciencesNASDAQ:COGTSIGA TechnologiesNASDAQ:SIGADianthus TherapeuticsNASDAQ:DNTHPharming GroupNASDAQ:PHARSavaraNASDAQ:SVRAView All Competitors STML Stock Analysis - Frequently Asked Questions How were Stemline Therapeutics' earnings last quarter? Stemline Therapeutics Inc (NASDAQ:STML) announced its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.08. The biopharmaceutical company earned $13.33 million during the quarter, compared to analysts' expectations of $13.40 million. Stemline Therapeutics had a negative trailing twelve-month return on equity of 48.14% and a negative net margin of 150.30%. What other stocks do shareholders of Stemline Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stemline Therapeutics investors own include TG Therapeutics (TGTX), Gilead Sciences (GILD), Viking Therapeutics (VKTX), ZIOPHARM Oncology (ZIOP), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Bausch Health Companies (BHC), FireEye (FEYE), NVIDIA (NVDA) and Sorrento Therapeutics (SRNE). This page (NASDAQ:STML) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersMysterious Gold Leverage Just AnnouncedStansberry ResearchThe only AI company you should be looking atBehind the MarketsDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stemline Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.